Stem and Progenitor Cell-Based Therapy of the Central Nervous System: Hopes, Hype, and Wishful Thinking.
Stem and Progenitor Cell-Based Therapy of the Central Nervous System: Hopes, Hype, and Wishful Thinking.
复制标题
DOI：
10.1016/j.stem.2016.01.012
复制
发表时间：
2016-02-04
期刊：
影响因子：
23.9
通讯作者：
Goldman SA
中科院分区：
文献类型：
--
作者：
Goldman SA
各种神经疾病是基于干细胞和祖细胞的治疗的有吸引力的靶点。然而，无论是由于不适宜居住的疾病环境、对病理生理学知之甚少，还是由于供体细胞能力与患者需求的不匹配，许多情况都不是这样。此外，一些疾病可能是医学上可行的目标，但鉴于已有的治疗方法、较差的风险效益和成本效益概况，或资源限制，这些目标是不可行的。这一视角试图通过考虑细胞替代疗法在这些疾病中的潜在疗效和临床可行性，以及其应用的潜在障碍，来定义最适合细胞替代疗法的神经疾病。
A variety of neurological disorders are attractive targets for stem and progenitor cell-based therapy. Yet many conditions are not, whether by virtue of an inhospitable disease environment, poorly understood pathophysiology, or poor alignment of donor cell capabilities with patient needs. Moreover, some disorders may be medically feasible targets, but are not practicable, in light of already available treatments, poor risk-benefit and cost-benefit profiles, or resource limitations. This Perspective seeks to define those neurological conditions most appropriate for cell replacement therapy, by considering its potential efficacy and clinical feasibility in those disorders, as well as potential impediments to its application.